Xcout IntelSign inSubscribe

EPITOMEE MED

EPITHealthtechCaesarea, Israel

Epitomee Medical Ltd develops and commercializes ingestible therapeutic devices in Israel. The company offers capsules for the treatment of overweight and obesity. It also focuses on developing biologic drug delivery solutions. Epitomee Medical Ltd was incorporated in 2005 and is based in Caesarea, Israel.

Subscribe to see EPITOMEE MED’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

EPITOMEE MED at a glance

EPITOMEE MED is a healthtech company headquartered in Caesarea, Israel. It is publicly listed (EPIT) with a market capitalisation of $33.7M. Xcout tracks 14 named people at EPITOMEE MED, including Dan Hashimshony (Chief Executive Officer).

Industry
Healthtech
Headquarters
Caesarea, Israel
Market cap
$33.7M
Employees
44
Ticker
EPIT

EPITOMEE MED leadership

  • Dan HashimshonyChief Executive Officer
  • Gal AharonowitzCOO
  • Maya GabrieliCFO
  • Shimon EckhouseCo-Founder and Chairman of the Board
  • Alon HethVP Sales and Marketing
  • Gil CohenVP Research & Development

8 more named people on record for EPITOMEE MED, with roles, board committees and tenure — see the full roster →

Recent EPITOMEE MED news

EPITOMEE MED competitors

A few of EPITOMEE MED's closest competitors — see the full list of competitors and alternatives →

InModeINMD · Aesthetics, Medical TechnologyYokne'am, Israel
64% matchPublic

InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.

Market cap$863.4M
Employees660
InMode competitors & alternatives →

Get EPITOMEE MED's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

EPITOMEE MED — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on EPITOMEE MED in Xcout Intel

  • 14 named people with titles, LinkedIn and board committees
  • 1 corporate event with sources — deals, leadership changes, layoffs
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →